Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Clinigen Group plc (CLIN) Ordinary 0.1p

Sell:819.00p Buy:819.50p 0 Change: No change
FTSE AIM 100:0.14%
Market closed |  Prices as at close on 23 April 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:819.00p
Buy:819.50p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 23 April 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:819.00p
Buy:819.50p
Change: No change
Market closed |  Prices as at close on 23 April 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.

Contact details

Address:
Pitcairn House
Crown Square, First Avenue
STAFFORDSHIRE
DE14 2WW
United Kingdom
Telephone:
+44 (01283) 495010
Website:
www.clinigengroup.com/

Important dates

Future events
There are no future events available.
Past events
Interim dividend payment date 13 April 2021 13/04/21
Interim ex-dividend date 18 March 2021 18/03/21
Interim results 23 February 2021 23/02/21
Trading Announcement 14 January 2021 14/01/21
Final dividend payment date 02 December 2020 02/12/20
AGM 26 November 2020 26/11/20
Trading Announcement 26 November 2020 26/11/20
Final ex-dividend date 05 November 2020 05/11/20
Annual report 05 October 2020 05/10/20
Final results 17 September 2020 17/09/20
Trading Announcement 14 July 2020 14/07/20

General stock information

EPIC:
CLIN
ISIN:
GB00B89J2419
Market cap:
£1.09 billion
Shares in issue:
133.03 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Shaun Chilton
    Chief Executive Officer, Director
  • Nick Keher
    Group Chief Financial Officer, Executive Director
  • Sam Herbert
    Chief Operating Officer
  • Amanda Miller
    General Counsel, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.